Previous study reported that FDA-approved drug ivacaftor targets cystic fibrosis transmembrane conductance regulator (CFTR) to treat cystic fibrosis, and CFTR has been indicated to facilitate glioma progression (Zhao et al., 2020). The gene discussed is CFTR; the disease is cystic fibrosis.